Document is current
Any future updates will be listed below
-
Authors
Smith, Ruben https://orcid.org/0000-0001-7147-0112
Shaw, Leslie
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Mattsson-Carlgren, Niklas
Klein, Gregory
Tonietto, Matteo https://orcid.org/0000-0001-9591-5710
,
Quijano-Rubio, Clara https://orcid.org/0000-0001-9050-3282
Rank, Christopher M.
Andreadou, Myrto https://orcid.org/0000-0001-6757-4664
Burnham, Samantha C.
Stomrud, Erik https://orcid.org/0000-0002-0841-5580
-
Funding
Funding for this research was provided by:
Roche Diagnostics International Ltd
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 29 May 2025
Accepted: 30 June 2025
First Online: 20 July 2025
Declarations
:
: The study was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland and Eli Lilly and Company, Indianapolis, IN, USA. The Elecsys Phospho-Tau (181P) CSF and Elecsys β-Amyloid (1–42) CSF II immunoassays used in the study were manufactured and supplied by Roche Diagnostics International Ltd. Ruben Smith has received consultancy and speaker fees from Eli Lilly, Novo Nordisk, Roche, and Triolab. Clara Quijano-Rubio and Myrto Andreadou are full-time employees of Roche Diagnostics International Ltd, Rotkreuz, Switzerland. Christopher M. Rank is a full-time employee of Roche Diagnostics GmbH, Penzberg, Germany, and shareholder of F. Hoffmann-La Roche Ltd. Matteo Tonietto and Gregory Klein are full-time employees and shareholders of F. Hoffmann-La Roche Ltd. Samantha C. Burnham is a full-time employee of Eli Lilly and Company and holds company stocks. Leslie Shaw, Sebastian Palmqvist, Niklas Mattsson-Carlgren, and Erik Stomrud have nothing to disclose.
: The study was conducted according to the principles of the Declaration of Helsinki. All samples from the BioFINDER-2 and ADNI-2/3 studies were collected under separate collection study protocols, under the control of the original study investigators with regard to the informed consent forms and recruitment. Ethics approval was received for the Swedish BioFINDER-2 study from the Regional Ethics Committee in Lund, Sweden. Written informed consent was obtained from each subject prior to enrolment into the ADNI-2/3 and Swedish BioFINDER-2 studies. All sample information and all required clinical information were pseudonymized.
